The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including MetAp-2 inhibitory compound, or s salt, ester, or prodrug thereof, effective to result in weight loss in the subject.
